[1] 颜子杰,康渝,刘书蔓,等. 益智仁激活PPARα介导的自噬作用改善糖尿病肾病[J]. 海南医学院学报,2024,30(17):1281-1289. DOI:10.13210/j.cnki.jhmu.20240518.001.
[2] 张微,胡凤交,姚春秀,等. 我国糖尿病肾病发病机制研究热点的可视化分析[J]. 中华预防医学杂志,2023,57(7):1075-1081. DOI:10.3760/cma.j.cn112150-20230119- 00050.
[3] 周桃桃,郭兆安. 糖尿病肾病发病机制研究进展[J]. 现代中西医结合杂志,2021,30(34):3872-3876. DOI:10.3969/j.issn.1008-8849.2021.34.025.
[4] 鞠丽丽,方敬爱,常沁涛. 尾加压素Ⅱ在糖尿病肾病发病中的作用机制研究进展[J]. 中西医结合心脑血管病杂志,2021,19(21):3702-3705. DOI:10.12102/j.issn.1672- 1349. 2021.21.013.
[5] 胡煜琳,杜晓刚. 血脂水平及血脂异常不同临床分类与糖尿病肾病的相关性及预测价值研究[J]. 四川大学学报(医学版),2023,54(5):1013-1018. DOI:10.12182/20230960103.
[6] 姜晓雪,金智生,金彩云,等. miRNA相关信号通路对糖尿病肾病的作用机制及中医药干预研究进展[J]. 中国实验方剂学杂志,2023,29(4):228-235. DOI:10.13422/j.cnki.syfjx.20222341.
[7] 梁衍,朱燕亭,高妍婷,等. PI3K/Akt/mTOR信号通路上调miR-155对糖尿病肾病大鼠的干预效果[J]. 河北医药,2023,45(12):1785-1788,1793. DOI:10.3969/j.issn. 1002-7386.2023.12.005.
[8] 杜菲菲,马越. miR-155、miR-146a在糖尿病肾病患者血清中的表达及诊断价值[J]. 中国医师杂志,2020,22(12):1831-1835. DOI:10.3760/cma.j.cn431274-20191011 -01159.
[9] Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation[J]. Diabet Med, 1998,15(7):539-553. DOI: 10.1002/(SICI)1096-9136 (199807)15:7539::AID-DIA6683.0.CO;2-S.
[10] 陈潇. 基于决策树分类模型的糖尿病肾病进展预测量表的研制[J]. 昆明医科大学学报,2024,45(8):109-116. DOI:10.12259/j.issn.2095-610X.S20240816.
[11] 郭宝珠,刘俊芬,韩小丽,等. 外周血单个核细胞中DUSP6预警糖尿病肾病腹膜透析后不良心血管事件的价值[J]. 中南大学学报(医学版),2024,49(3):359-366. DOI:10.11817/j.issn.1672-7347.2024.230496.
[12] 贺婕,张会娟. 糖尿病患者病程及血清胱抑素C水平与糖尿病肾病的关系[J]. 中国实用医刊,2011,38(11):37-39. DOI:10.3760/cma.j.issn.1674-4756.2011.11.015.
[13] 田蓉,傅桂芬,李丽蓉,等. 老年T2DM合并高血压患者发生糖尿病肾病的影响因素[J]. 心血管康复医学杂志,2023,32(1):4-8. DOI:10.3969/j.issn.1008-0074.2023.01.02.
[14] 李春蒙,廖晓辉. 新型炎症指数在糖尿病肾病患者全因死亡中的预测价值[J]. 现代医药卫生,2024,40(17):2881-2887. DOI:10.3969/j.issn.1009-5519.2024.17.001.
[15] 李攀红,蒲涛,于泓. 糖尿病肾病肾小管上皮细胞脂质代谢紊乱的研究进展[J]. 海南医学,2021,32(8):1030-1035. DOI:10.3969/j.issn.1003-6350.2021.08.022.
[16] 关昌杰,何凤,周姗姗,等. MiR-155调控Smad5促进糖尿病肾病肾脏纤维化作用[J]. 实用医学杂志,2017,33(20):3340-3344. DOI:10.3969/j.issn.1006-5725.2017.20.003.
[17] Chen HH, Huang YL, Chen MC, et al. Chronic kidney disease: interaction of adiponectin gene polymorphisms and diabetes[J]. Int J Mol Sci, 2023,24(9):8128. DOI: 10.3390/ijms24098128.
[18] Dias GD, Cartolano FC, Freitas MCP,et al. Adiponectin predicts the antioxidant capacity and size of high-density lipoprotein (HDL) in individuals with diabetes mellitus[J]. J Diabetes Complications, 2021,35(5):107856.DOI: 10.1016/j.jdiacomp.2021.107856.
[19] Ishizu M, Mori H, Ohishi M, et al. Urinary adiponectin excretion is an early predictive marker of the decline of the renal function in patients with diabetes mellitus[J]. J Diabetes Complications, 2021,35(4):107848. DOI: 10.1016/j.jdiacomp.2021.107848.
[20] Ohara M, Koike T, Tomoda F, et al. PS-C29-7: association of serum leptin to adiponectin ratio and cardiovascular structural indices in essential hypertensive patients without chronic kidney disease[J]. Journal of Hypertension, 2023, 41:e462. DOI:10.1097/01.hjh. 0000917600.90407.5c.
[21] 陈松姬,江婷,陈祖清. 2型糖尿病病人颈动脉内膜中层厚度与三酰甘油-葡萄糖指数相关性分析[J]. 岭南急诊医学杂志,2020,25(6):630-633. DOI:10.3969/j.issn.1671- 301X. 2020.06.027.
[22] 庞国珍,徐小梅,陈伟婵. 糖尿病肾病患者高密度脂蛋白水平与机体炎症反应及肾功能的相关性研究[J]. 深圳中西医结合杂志,2024,34(1):19-22. DOI:10.16458/j.cnki. 1007-0893.2024.01.005.
[23] Roumeliotis S, Liakopoulos V, Roumeliotis A, et al. Mutual effect modification between adiponectin and HDL as risk factors of cardiovascular events in type 2 diabetes individuals: a cohort study[J]. Int Urol Nephrol, 2021,53(12):2583-2591. DOI: 10.1007/s11255-021-02828-4.
[24] 刘文华,汤珊珊,魏双双,等. 白脂素与多囊卵巢综合征合并胰岛素抵抗的关系研究[J]. 浙江医学,2021,43(11):1217-1219,1230. DOI:10.12056/j.issn.1006-2785. 2021.43.11.2020-1220.
[25] Jankauskas SS, Gambardella J, Sardu C, et al. Functional role of miR-155 in the pathogenesis of diabetes mellitus and its complications[J]. Noncoding RNA, 2021,7(3):39. DOI: 10.3390/ncrna7030039.
|